<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stuart Berger, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Triedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Attention deficit hyperactivity disorder (ADHD) is a common childhood disorder, affecting approximately 5 to 15 percent of all school-aged children. Stimulant drugs and other pharmacologic agents are commonly used for treatment of ADHD.</p><p>Reports of sudden unexpected deaths among patients taking stimulant drugs for ADHD led to concerns regarding the safety of ADHD medications. These findings were not confirmed in subsequent large cohort studies. Nevertheless, the question of whether ADHD medication increases the risk of adverse cardiovascular (CV) events continues to be debated, and uncertainties remain as to what pretreatment evaluation is necessary (if any) prior to starting stimulant medications to identify patients who may be at increased risk for arrhythmia and sudden cardiac death (SCD).</p><p>The risk of serious CV events, including SCD, in patients receiving ADHD medications and the pretreatment cardiac evaluation for such patients will be reviewed here. Other related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/602.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85989.html" rel="external">"Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in children"</a>.)</p><p></p><p class="headingAnchor" id="H2227255154"><span class="h1">PHYSIOLOGIC EFFECTS OF ADHD MEDICATIONS</span></p><p class="headingAnchor" id="H3689848950"><span class="h2">Stimulant medications</span><span class="headingEndMark"> — </span>Stimulant drugs (eg, <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a>, <a class="drug drug_pediatric" data-topicid="13010" href="/z/d/drug information/13010.html" rel="external">dexmethylphenidate</a>, <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">dextroamphetamine</a>, <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">dextroamphetamine-amphetamine</a>) have known effects on heart rate (HR) and blood pressure (BP). However, these effects are generally modest and, in most cases, they are not clinically significant. </p><p>In studies evaluating stimulant medications, the reported changes in HR and BP were [<a href="#rid1">1-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>HR increases ranged from 3 to 10 beats per minute</p><p class="bulletIndent1"><span class="glyph">●</span>Systolic BP increases ranged from 3 to 8 mmHg</p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic BP increases ranged from 2 to 6 mmHg</p><p></p><p>The pharmacology of these agents is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Stimulants'</a>.)</p><p class="headingAnchor" id="H110554967"><span class="h2">Nonstimulants</span><span class="headingEndMark"> — </span>Nonstimulant medications used to treat ADHD include selective norepinephrine reuptake inhibitors (eg, <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">atomoxetine</a>, <a class="drug drug_pediatric" data-topicid="131245" href="/z/d/drug information/131245.html" rel="external">viloxazine</a>) and alpha-2 adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a>, <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>). (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Atomoxetine – In a comprehensive review of a clinical trial database that included &gt;8000 patients treated with <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">atomoxetine</a>, most pediatric patients experienced modest increases in heart rate and blood pressure and 8 to 12 percent experienced more pronounced changes (≥20 beats per minute, ≥15 to 20 mmHg) [<a href="#rid8">8</a>]. Thus, the prescribing information for atomoxetine includes a warning that the drug "generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to its noradrenergic effects" [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Atomoxetine adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-2 adrenergic agonists – Alpha-2 adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a>, <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>) have known cardiovascular side effects which can include bradycardia and hypotension. Clinically significant HR and BP changes are uncommon when these drugs are used at the typical doses for ADHD treatment. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Alpha-2-adrenergic agonists'</a>.) </p><p></p><p class="headingAnchor" id="H2"><span class="h1">RISK OF ADVERSE CARDIOVASCULAR EVENTS</span><span class="headingEndMark"> — </span>In the late 2000s, reports of unexpected deaths among children receiving stimulant therapy led to concerns that these medications may increase the risk of adverse cardiovascular (CV) events, including sudden cardiac death (SCD) [<a href="#rid10">10-12</a>]. However, large cohort studies have not shown an increased risk of serious CV adverse events in individuals treated with stimulant therapy compared with the general population, as discussed in the following section [<a href="#rid13">13-17</a>].</p><p class="headingAnchor" id="H3"><span class="h2">General population</span><span class="headingEndMark"> — </span>Based on the available evidence, there does <strong>not</strong> appear to be an increased risk for adverse CV events associated with ADHD drugs in the general population.</p><p>In a meta-analysis of 19 studies (14 cohort studies, 3 nested case-control studies, and 2 before-after studies) including &gt;3.9 million patients (children and adolescents accounted for approximately 75 percent of the study populations) from various regions in the world (United States, South Korea, Canada, Denmark, Spain, and Hong Kong), the following findings were noted [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>No apparent association between ADHD medications and CV events</strong> – In the main analysis, the study did not detect an association between ADHD medication use and the overall risk of any adverse CV event (relative risk [RR] 1.22, 95% CI 0.88-1.68) [<a href="#rid17">17</a>]. In an analysis limited to only studies evaluating stimulant medications, there was also no apparent association (1.24, 95% CI 0.84-1.83).</p><p></p><p class="bulletIndent1">In subgroup analyses of studies involving different age groups, there was no apparent association between ADHD medications and CV events in any subpopulation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children and adolescents – RR 1.18, 95% CI 0.91-1.53</p><p class="bulletIndent2"><span class="glyph">•</span>Young and middle-aged adults – RR 1.04, 95% CI 0.43-2.48</p><p class="bulletIndent2"><span class="glyph">•</span>Older adults – RR 1.59, 95% CI 0.62-4.05</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific types of CV events </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SCD and tachyarrhythmias</strong> – It is unclear whether ADHD medication use is associated with increased risk of SCD. If there is an effect, the absolute risk is very small. In an analysis of nine studies that reported rates of SCD, cardiac arrest, or tachyarrhythmia, the pooled risk was slightly higher among individuals using ADHD medications, but the finding was not statistically significant (RR 1.60, 95% CI 0.94-2.72) [<a href="#rid17">17</a>]. The studies in this analysis involved both pediatric (four studies) and adult (five studies) populations.</p><p></p><p class="bulletIndent2">The absolute risk of SCD in these studies was exceedingly low. For example, in the largest study in the meta-analysis which included &gt;1,200,000 children and young adults (ages 2 to 24 years), the overall rate of SCD was 1.3 per 100,000 patients per year (1.6 per 100,000 patient-years among individuals with current or prior ADHD medication use versus 1.1 per 100,000 person-years among non-users) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myocardial infarction (MI) </strong>– In an analysis of eight studies reporting rates of MI, there was no apparent association between ADHD medications and MI (RR 1.06, 95% CI 0.68-1.65) [<a href="#rid17">17</a>]. Most of studies in this analysis (six of eight) involved adult populations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stroke </strong>– In an analysis of 10 studies reporting rates of stroke, there was no apparent association between ADHD medications and cerebrovascular diseases (RR 0.91, 95% CI 72-1.15) [<a href="#rid17">17</a>]. The studies in this analysis involved both pediatric (four studies) and adult (six studies) populations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with prior CV disease</strong> – In a meta-analysis of seven studies involving patients with prior CV disease history, there was no apparent association between ADHD medications and risk of adverse CV events (RR 1.31, 95% CI 0.80-2.16) [<a href="#rid17">17</a>]. However, the studies in the meta-analysis largely used diagnostic codes from medical billing to identify patients with prior CV history, and the definition was very broad. As discussed below, children with serious cardiac conditions (eg, complex congenital heart disease [CHD], cardiomyopathy) were not well represented in these studies. (See <a class="local">'Children with cardiac disease'</a> below.)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Children with cardiac disease</span><span class="headingEndMark"> — </span>No studies to date have demonstrated that ADHD medications increase the risk of SCD in children with congenital or acquired heart disease. However, few studies have adequately evaluated the safety of stimulant drugs in this population. For example, there are few studies on the use of ADHD medications specifically in children with complex CHD, among whom ADHD is a common comorbidity [<a href="#rid18">18,19</a>]. </p><p>There are no specific cardiac diagnoses in which ADHD medications are absolutely contraindicated. However, caution should be used when prescribing ADHD medications in children with underlying conditions in which the known physiologic effects of stimulant medications (ie, modest increase in heart rate and blood pressure) might be poorly tolerated. This includes [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with poorly controlled hypertension (see  <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with arrhythmia syndromes (eg, long QT syndrome, Brugada syndrome, Wolff-Parkinson-White syndrome) [<a href="#rid21">21</a>] (see  <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">"Congenital long QT syndrome: Diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">"Brugada syndrome: Clinical presentation, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with symptomatic cardiomyopathy (eg, dilated cardiomyopathy, hypertrophic cardiomyopathy) (see  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/z/d/html/4951.html" rel="external">"Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with aortic root disease (eg, Marfan syndrome) (see  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>)</p><p></p><p>In these conditions, decisions regarding initiation of pharmacotherapy for ADHD are individualized and should be made in collaboration with the family/caregivers and the child's cardiologist. If ADHD medication is used in such patients, close monitoring is advised. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h1">PRETREATMENT CLINICAL EVALUATION</span><span class="headingEndMark"> — </span>Prior to initiating medication for ADHD in children and adolescents, we suggest performing a clinical evaluation aimed at identifying underlying cardiac disease that may predispose the child to sudden cardiac death (SCD) or other serious cardiovascular events. This generally includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive medical history with particular attention to warning signs for cardiac disease (eg, unexplained syncope, chest pain or dyspnea with exercise) (see  <a class="medical medical_review" href="/z/d/html/85989.html" rel="external">"Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in children", section on 'Warning signs'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history, including whether any family members have experienced SCD or life-threatening cardiac arrhythmias </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of blood pressure and heart rate</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac auscultation to detect the presence of a heart murmur, or irregular or rapid heart rhythm (see  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical findings associated with Marfan syndrome (see  <a class="medical medical_review" href="/z/d/html/8150.html" rel="external">"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders"</a>)</p><p></p><p>If the history and examination do not suggest cardiac disease, the available evidence suggests that ADHD pharmacotherapy can be safely initiated<strong> without</strong> any additional evaluation [<a href="#rid22">22,23</a>]. (See <a class="local">'No role for routine ECG screening'</a> below.)</p><p>If there are concerns for cardiac disease based upon the clinical evaluation, additional evaluation may be warranted under the direction of a pediatric cardiologist. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5765.html" rel="external">"Suspected heart disease in infants and children: Criteria for referral"</a>.)</p><p>For children with suspected or known cardiac disease, decisions regarding initiation of pharmacotherapy for ADHD are individualized and should be made in collaboration with the family/caregivers and the child's cardiologist. Based upon the available evidence, there are no specific cardiac diagnoses in which ADHD medications are absolutely contraindicated. However, when prescribing these medications in children with serious cardiac disease, it is prudent to consider the known physiologic effects of stimulant medications (ie, modest increase in heart rate and blood pressure). If ADHD medications are used in patients with serious cardiac disease, close monitoring is advised. (See <a class="local">'Children with cardiac disease'</a> above and <a class="local">'Monitoring'</a> below.)</p><p>Our approach is generally consistent with the recommendations of the American Academy of Pediatrics and the American Heart Association [<a href="#rid23">23</a>]. This approach is also endorsed by several other professional organizations, including the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder, the National Institute for Children's Health Quality, and the Society for Developmental and Behavioral Pediatrics.</p><p>However, it is important to note that based upon the available evidence, it remains uncertain if there truly is an association between stimulant use and SCD. If there is an effect, the absolute risk is very small. What is clear, however, is that limiting or delaying a child's access to effective treatment for ADHD could have serious implications (such as increased risk of adolescent substance use disorder, academic failure, and accidents) in patients who are not effectively treated. These relative risks should be discussed with families/caregivers. (See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis", section on 'Prognosis'</a>.) </p><p class="headingAnchor" id="H10775178"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>During treatment with ADHD stimulant therapy, the patient should be assessed for any new symptoms (eg, fainting or dizziness, chest pain or shortness of breath with exercise, unexplained change in exercise tolerance, or palpitations). Evaluation should include measurement of heart rate and blood pressure to ascertain whether there have been any significant changes compared with pretreatment values, especially if the blood pressure reaches either prehypertension or hypertension levels. (See  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a>.)</p><p>In patients with concerning symptoms or findings, consultation with a pediatric cardiologist is advised. (See  <a class="medical medical_review" href="/z/d/html/5765.html" rel="external">"Suspected heart disease in infants and children: Criteria for referral"</a>.)</p><p class="headingAnchor" id="H1993056883"><span class="h1">NO ROLE FOR ROUTINE ECG SCREENING</span><span class="headingEndMark"> — </span>An electrocardiogram (ECG) is <strong>not</strong> required before initiating ADHD medication. This is because:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidences of arrhythmia and sudden cardiac death (SCD) do not appear to be significantly increased in children receiving ADHD medications. (See <a class="local">'Risk of adverse cardiovascular events'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ECG has a poor sensitivity and specificity for identifying individuals at risk for SCD [<a href="#rid24">24</a>]. False positives are common and false negatives can also occur. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85989.html" rel="external">"Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in children", section on 'Screening at routine health care visits'</a>.)</p><p></p><p class="headingAnchor" id="H2353221768"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117871.html" rel="external">"Society guideline links: Attention deficit hyperactivity disorder"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiologic effects of ADHD medications</strong> – Medications that are used to treat attention deficit hyperactivity disorder (ADHD) include stimulants, selective norepinephrine reuptake inhibitors (SNRIs), and alpha-2 adrenergic agonists. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents"</a>.) </p><p></p><p class="bulletIndent1">These drugs have known effects on heart rate (HR) and blood pressure (BP): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stimulant medications</strong> – In studies evaluating stimulant medications (eg, <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a>, <a class="drug drug_pediatric" data-topicid="13010" href="/z/d/drug information/13010.html" rel="external">dexmethylphenidate</a>, <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">dextroamphetamine</a>, <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">dextroamphetamine-amphetamine</a>), the reported changes in HR and BP were (see <a class="local">'Stimulant medications'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>HR increases ranged from 3 to 10 beats per minute (bpm)</p><p class="bulletIndent3"><span class="glyph">-</span>Systolic BP increases ranged from 3 to 8 mmHg</p><p class="bulletIndent3"><span class="glyph">-</span>Diastolic BP increases ranged from 2 to 6 mmHg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SNRIs</strong> – In studies evaluating <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">atomoxetine</a>, most patients experienced modest increases in HR and BP and approximately 10 percent experienced more pronounced changes (HR increase of ≥20 bpm, BP increase of ≥15 to 20 mmHg). (See <a class="local">'Nonstimulants'</a> above and  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Atomoxetine adverse effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alpha-2 adrenergic agonists</strong> – Alpha-2 adrenergic agonists (eg, <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a>, <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>) can cause bradycardia and, less commonly, hypotension. (See <a class="local">'Nonstimulants'</a> above and  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Alpha-2-adrenergic agonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of serious cardiovascular (CV) events</strong> – Following several reports of unexpected deaths in children receiving stimulant therapy, concerns arose about the risk of experiencing adverse CV events, particularly sudden cardiac death (SCD), when receiving ADHD medications. However, large cohort studies have not shown an increased risk of serious CV events in individuals treated with ADHD therapy (stimulant or nonstimulant) compared with the general population. (See <a class="local">'Risk of adverse cardiovascular events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – Prior to initiating medication for ADHD in children and adolescents, we suggest performing a clinical evaluation aimed at identifying underlying cardiac disease that may predispose the child to SCD or other serious cardiovascular events. This generally includes (see <a class="local">'Pretreatment clinical evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comprehensive medical history </p><p class="bulletIndent2"><span class="glyph">•</span>Family history</p><p class="bulletIndent2"><span class="glyph">•</span>Physical examination, including measurement of BP and HR, cardiac auscultation to identify heart murmurs or abnormal heart rhythm, and assessment for findings of Marfan syndrome</p><p></p><p class="bulletIndent1">If the history and examination do not suggest cardiac disease, ADHD pharmacotherapy can be initiated<strong> </strong>without any additional evaluation. A screening ECG is <strong>not</strong> required. (See <a class="local">'No role for routine ECG screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Children who are prescribed ADHD medications should be routinely evaluated for any changes in HR or BP, as well as CV symptoms during treatment. (See <a class="local">'Monitoring'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of ADHD medications in children with cardiac disease</strong> – No studies to date have demonstrated that ADHD medications increase the risk of SCD in children with congenital or acquired heart disease. However, few studies have adequately evaluated the safety of these drugs in this population. (See <a class="local">'Children with cardiac disease'</a> above.) </p><p></p><p class="bulletIndent1">There are no specific cardiac diagnoses in which ADHD medications are absolutely contraindicated. However, decisions regarding initiation of ADHD medication in patients with underlying cardiac disease are individualized and should be made in collaboration with the family/caregivers and the child's cardiologist. If ADHD medications are used in such patients, close monitoring is advised. (See <a class="local">'Monitoring'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005; 147:348.</a></li><li><a class="nounderline abstract_t">Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40:525.</a></li><li><a class="nounderline abstract_t">Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21:92.</a></li><li><a class="nounderline abstract_t">Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011; 50:978.</a></li><li><a class="nounderline abstract_t">Kelly AS, Rudser KD, Dengel DR, et al. Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants. J Pediatr 2014; 165:755.</a></li><li><a class="nounderline abstract_t">Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs 2017; 31:199.</a></li><li><a class="nounderline abstract_t">Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009; 155:84.</a></li><li><a class="nounderline abstract_t">Reed VA, Buitelaar JK, Anand E, et al. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. CNS Drugs 2016; 30:603.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021411s048lbl.pdf (Accessed on July 19, 2017).</li><li><a class="nounderline abstract_t">Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445.</a></li><li><a class="nounderline abstract_t">Gorman RL. FDA Panel recommends black box warning on ADHD stimulant medications. AAP News 2006; 27:16.</a></li><li><a class="nounderline abstract_t">Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166:992.</a></li><li><a class="nounderline abstract_t">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365:1896.</a></li><li><a class="nounderline abstract_t">Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127:1102.</a></li><li><a class="nounderline abstract_t">Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345:e4627.</a></li><li><a class="nounderline abstract_t">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306:2673.</a></li><li><a class="nounderline abstract_t">Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2243597.</a></li><li><a class="nounderline abstract_t">Gothelf D, Gruber R, Presburger G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 2003; 64:1163.</a></li><li><a class="nounderline abstract_t">Batra AS, Alexander ME, Silka MJ. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason. Pediatr Cardiol 2012; 33:394.</a></li><li><a class="nounderline abstract_t">Topriceanu CC, Moon JC, Captur G, Perera B. The use of attention-deficit hyperactivity disorder medications in cardiac disease. Front Neurosci 2022; 16:1020961.</a></li><li><a class="nounderline abstract_t">Zhang C, Kutyifa V, Moss AJ, et al. Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. J Cardiovasc Electrophysiol 2015; 26:1039.</a></li><li><a class="nounderline abstract_t">Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008; 122:451.</a></li><li class="breakAll">American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD. Available at: americanheart.mediaroom.com/index.php?s=43&amp;item=422 (Accessed on June 09, 2008).</li><li><a class="nounderline abstract_t">Mahle WT, Hebson C, Strieper MJ. Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol 2009; 104:1296.</a></li></ol></div><div id="topicVersionRevision">Topic 5763 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182674" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11349696" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Short-term cardiovascular effects of methylphenidate and adderall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254730" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21961773" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015574" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28236285" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394037" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27290715" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27290715" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549404" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ADHD drugs and cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : FDA Panel recommends black box warning on ADHD stimulant medications</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528194" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sudden death and use of stimulant medications in youths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22043968" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ADHD drugs and serious cardiovascular events in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576311" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cardiovascular events and death in children exposed and unexposed to ADHD agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22809800" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161946" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36416824" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14658963" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22298228" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36340760" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The use of attention-deficit hyperactivity disorder medications in cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26149510" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676566" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676566" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840580" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Electrocardiographic screening in children with attention-deficit hyperactivity disorder.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
